HOME >> MEDICINE >> NEWS
Cholesterol-lowering drug may slow Alzheimer's progression

NEW ORLEANS, Nov. 9 The cholesterol-lowering drug atorvastatin slowed down mental decline and improved depressive symptoms in people with Alzheimer's disease, according to a small pilot study reported at the American Heart Association's Scientific Sessions 2004.

"This is the first off-label use of a drug tested in Alzheimer's patients in the last 10 years that has shown promise of benefit," said D. Larry Sparks, Ph.D., senior scientist and head of the Roberts Laboratory for Neurodegenerative Disease Research at Sun Health Research Institute in Sun City, Ariz.

Animal and human studies have shown that elevated cholesterol is an important risk factor for Alzheimer's disease. Based on this research and Sparks's work for the past 20 years, he and colleagues in Bethesda, Md., New York City, Phoenix and Sun City, tested the effects of lowering cholesterol in people with mild-to-moderate Alzheimer's disease.

The Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT) was a double-blind, placebo-controlled pilot study that assessed whether lowering cholesterol with atorvastatin could stabilize or improve cognition in people with mild-to-moderate Alzheimer's. Doctors administered the statin drug in addition to the cholinesterase inhibitors the patients were already taking. Cholinesterase inhibitors are the only Food and Drug Administrationapproved therapy for mild-to-moderate Alzheimer's disease. The drugs inhibit the breakdown of acetylcholine, a transmitter that is decreased in Alzheimer's patients and thought to be related to mental decline.

The researchers evaluated 46 patients -- 25 on atorvastatin 80 mg and 21 on placebo -- for one year. The participants were, on average, 78-years-old with 14 years of education. One-third of the group was female. The patients were evaluated periodically for cognition, overall mental function and depression. Alzheimer's patients are known to have depression that usually gets worse as their Alzheimer
'"/>

Contact: Darcy Spitz
darcy.spitz@heart.org
212-878-5940
American Heart Association
9-Nov-2004


Page: 1 2 3

Related medicine news :

1. Cholesterol-lowering drug may also reduce risk of blood clots
2. Cholesterol-lowering medications may reduce risk of glaucoma
3. Cholesterol-lowering drugs may help stroke patients get well
4. Cholesterol-lowering drugs safe and effective in children
5. Cholesterol-lowering drugs should revolutionise treatment of heart attack and stroke
6. Cholesterol-lowering drugs provide double protection against heart disease
7. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
8. Neuronal death and processing of Tau protein in Alzheimers disease
9. Researchers discover link between insulin and Alzheimers
10. New trials for counseling caregivers and patients with Alzheimers begin
11. Marijuana ingredient may stall decline from Alzheimers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cholesterol lowering drug may slow Alzheimer progression

(Date:6/18/2013)... June 18, 2013 David Connett, DO, ... Family Medicine for the College of Osteopathic Medicine of ... has been elected president of the Osteopathic Medical ... Brown Jr. appointed Connett, a 1984 alumnus of COMP, ... recently elected Connett to the position during a conference ...
(Date:6/18/2013)... N.Y., June 18, 2013 -- Lauren Sciences, a ... V-Smart nanovesicle platform technology, announced today that it ... Drug Delivery with its V-Smart Platform, and selected ... by MCD Group. , The report, ... Start-ups and Emerging Companies ," features companies MCD ...
(Date:6/18/2013)... enrolled their first patients in the ROADSTER Study, a ... to help clear blockages in carotid arteries and prevent ... in the United States are diagnosed with blockages, or ... blockages can slow or even stop blood flow to ... as a "brain attack." , Current treatment options ...
(Date:6/18/2013)... scrambling to gather data for the FDA to support ... injury in the United States. The University of Rochester ... the Journal of Neurotrauma that it might ... of one., Jeffrey J. Bazarian, M.D., M.P.H., an associate ... first to show that measuring a combination of two ...
(Date:6/18/2013)... system using a person,s DNA was announced as ... London Startup Competition, Europe,s largest technology conference. ... on University of Bristol research by its founders, ... Professor of Bioinformatics in the University,s Department of ... to be one of 16 finalists in the ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center among first to enroll patients for global carotid artery trial 2
(Date:6/18/2013)... 18, 2013  Cataracts are the leading cause of ... of Ophthalmology, aging is the leading cause of eye ... natural lens. 22 million Americans age 40 and older ... to age, that number will increase over 30 million. ... iPads, smart-phones and computers, the demographic of ages 40 ...
(Date:6/18/2013)... , June 18, 2013  Decision Resources, ... firms for pharmaceutical and healthcare issues, announces that ... of the Middle East ... Tracker analyzes the challenges and opportunities to gaining ... international regions comprising 24 countries. The countries covered ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 ... Gilead Sciences, Inc. (NASDAQ: GILD ), Health Management ... (NASDAQ: IDXX ), ISIS Pharmaceuticals Inc. (NASDAQ: ... readers may access these reports free of charge - including ... the links below. Gilead Sciences, Inc. Research Report ...
Breaking Medicine Technology:New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
Cached News: